Effectiveness and tolerability of fixed-dose combinations of telmisartan in patients with hypertension with metabolic syndrome and without metabolic changes

Aim. To evaluate the effectiveness and tolerability of antihypertensive therapy with fixed combinations of telmisartan in patients with hypertension (Htn) in the presence or absence of metabolic syndrome (MS).

Materials and methods. A total of 5985 patients were included in the study: 1879 were group 1 (Htn without metabolic disorders) and 4106 were group 2 (Htn combined with MS). The duration of follow-up was 12 weeks. Blood pressure and heart rate dynamics were evaluated in all patients, and additionally in the group of patients with MS body mass index, waist circumference and hip circumference were assessed. Tolerability was evaluated on the basis of completed questionnaires in Likert scale scores and data on adverse events.

Results. After 12 weeks of taking the combination of telmisartan and amlodipine in the hypertension group without metabolic disorders, the target level of systolic blood pressure (SBP) was <140 mmHg. reached 92% of patients, the target diastolic blood pressure (DBP) level was achieved in 96% of patients. While taking a combination of telmisartan and hydrochlorothiazide, the SBP level was <140 mmHg. was recorded in 92% of patients, target DBP<90 mmHg. was recorded in 96% of patients. After 12 weeks of taking the combination of telmisartan and amlodipine in the hypertension group in combination with MS, the target SBP level was <140 mmHg. reached 89% of patients, level <90 mmHg. 93% of patients achieved target DBP levels. During a similar period of taking the combination of telmisartan and hydrochlorothiazide, the target SBP level was <140 mmHg. reached 90% of patients, level <90 mmHg. 94% of patients achieved target DBP levels. The vast majority of physicians and patients (97–98%) evaluated the efficacy and tolerability of telmisartan-based fixed combinations as good to very good. No serious adverse events were registered.

Conclusion. During therapy with fixed combinations of telmisartan and amlodipine, telmisartan and hydrochlorthiazide a high level of achievement of target values of blood pressure was observed both in the group of patients with hypertension and in the group of patients with hypertension combined with metabolic syndrome, which is more difficult from the point of view of treatment effectiveness.